Global Biosimulation Market Overview

The global Biosimulation Market size was valued at USD 4.31 Billion in 2023 and is projected to reach USD 16.69 Billion by 2032, growing at a CAGR of 16.23 % from 2024 to 2032.

Biosimulation involves the use of computer-aided mathematical models to simulate biological processes and systems, playing a crucial role in systems biology. Given the intricate nature of biological systems, simplified models are often employed to manage complexity. These models are designed to be as detailed as necessary to accurately reflect the processes under study.

• The biosimulation market is rapidly expanding as pharmaceutical and biotechnology companies increasingly adopt these tools to streamline drug discovery and development processes. By providing insights into the likely outcomes of biological experiments, biosimulation helps in reducing the time and costs associated with clinical trials. This technology also supports personalized medicine by predicting individual responses to drugs, leading to more effective and tailored treatments.
• With advancements in computational power and machine learning, the capabilities of biosimulation are continually improving. This is driving its adoption across various sectors, including healthcare, where it is used to model disease progression and treatment outcomes. The growing need for precision medicine, coupled with the demand for more efficient drug development processes, is expected to fuel the growth of the biosimulation market in the coming years.
• In addition, regulatory bodies are increasingly recognizing the value of biosimulation in drug approval processes, further boosting its adoption. As technology becomes more sophisticated, it is likely to play an even more significant role in the future of biomedical research and development.

Market Dynamics And Factors For Biosimulation Market

Drivers:

Growth in the Development of Biologics and Biosimilar

The demand for biologics across the healthcare sectors is increased is the major factor that supports the growth of the biosimulation market. In the last few years growing the incidence of chronic diseases and their diagnosis worldwide. For instance, Statista stated that around 19.2 million new cancer cases were present in 2020 in the world. According to WHO, 41 million deaths occur due to non-communicable diseases in 2021. The following diagram shows that death occurs due to non-communicable diseases in 2021.

Thus, due to the growing prevalence of diseases, the market players rising their investment in the research and development of biologics. For instance, Cadila Pharmaceuticals launched two similar biologics such as NuPTH and Cadalimab in the Indian market in October 2020. Moreover, technological advancement, and rising government funding in the R&D activities of oral biologics which rising the demand for biosimulation technologies that provide growth for the biosimulation market.

Restraints:

Lack of Standardisation For Model Representation

The lack of standardization for model representation of the biosimulation technology is the key factor that restricts the growth of the biosimulation market. Biosimulation utilizes different types of models, tools, and languages for capturing and processing various aspects of biological processes. For building and managing complex biosimulation systems, advanced technology has improved the computational power of biomedical researchers. As the model and simulation grow in complexity, it is more difficult to share, manage and edit models for researchers. The problem of sharing models becomes more critical with the lack of standardization for model representation which hampers the growth of the biosimulation market.

Opportunity:

Growing Government Funding In The R&D Activities

The government of various countries’ rising investment in the research and development of drugs is providing a lucrative opportunity for the biosimulation market during the forecast period.  The research and development sectors spent on the discovery and evaluation of the new drug.  Owing to the growing prevalence of chronic diseases with the death rate, rising concern about the diseases among people.  Thus, for the treatment of these diseases, the government funds more for the development of novel drugs. For instance, according to Statista, the Germany and United States are the leading sources in the investment of research and development, and they putting 1.5 billion and 2 billion into the development of the covid-19 vaccines respectively. Thus, government investment offers a remunerative opportunity for the biosimulation market in the forecast period.

Segmentation Analysis Of Biosimulation Market

By Product Type, the software segment is expected to have the maximum share in the biosimulation market during the forecast period. The biosimulation software includes PBPK modeling and simulation software, lecular modeling and simulation software, trial design software, PK/PD modeling and simulation software, toxicity prediction software, and other biosimulation software. In pharmaceutical, biotechnological companies, and research organizations there is increased demand for biosimulation due to they are continuously engaged in the research and development of different kinds of novel drugs. The growing government support for the activities related to research studies. The market players installing the new advanced technology in biosimulation software to improve the drug development process. For instance, In June 2022, a global leader in biosimulation, Certara launched a new version of biosimulation software for the development of novel biologics. This latest version helps to tackle challenges in drug discovery and development with complex biologics. Thus, the software has maximum growth in the biosimulation market.

By Application, drug development is projected to have the largest share in the biosimulation market during the analysis period. The pharmaceutical, biotechnological, and research organizations increasing biosimulation adoption for controlling the costs in the drug development process. The US FDA stated that biosimulation is the most useful tool in the drug development process. In the last few decades, the prevalence of chronic diseases is increased in the world. Thus, the government of various countries also healthcare organization major in investing in drug development. Clinical studies are the most crucial part of drug development. According to Statista in the recent year constantly rising registered number of clinical trials. As of 28 March 2022, there were more than 409 thousand clinical studies registered worldwide. Henceforth, due to the growing drug development processes, the adoption of biosimulation is increased which propels the growth of the biosimulation market.

By End-Users, the pharmaceutical and biotechnological companies have the maximum share in the biosimulation market. The pharmaceutical and biotechnological companies continuously engaged in the drug discovery and development process. The following figure shows the expenditure of the total US pharmaceutical companies in research and development from 2017-2021.

Moreover, due to the rising prevalence of chronic diseases, the government increasing its funding for the development of pharmaceutical as well as biotechnological companies. Thus, the adoption of biosimulation is dominant in pharmaceutical and biotechnological companies which boosts the biosimulation market.

Regional Analysis Of Biosimulation Market

North America is the dominant region in the biosimulation market owing to growing the research and development of novel drugs. In this region rising the prevalence of chronic diseases such as cancer, and cardiovascular diseases, the government, and healthcare sectors increasing their investment in the development of the new drug. For instance, as per the report of the Centers for disease control and prevention, there were 697,000 people died in the year 2020 in United State. The US is dominant in North America for the biosimulation market. The Food and Drug Administration (FDA) of the US strongly suggested the simulation process in drug discovery and development. For instance, according to the report of theclinicaltrials.gov. there are 134,116 clinical trials going on in the United State as of 8th August 2022.  The covid-19 changed the demand for clinical trials in the US. The major players in this region adopting digital and automation technologies. In May 2022, the US FDA certified the renewal license of DILIsym software platform of Simulations Plus a key provider of modeling and simulation software and services for pharmaceutical safety and efficacy. Thus, the growing launching of new drugs and growing government funding in the research and development of the drugs rising the demand for biosimulation technologies that propel the growth of the market biosimulation in the North American region.

The Asia Pacific is the second-dominated region in the market of biosimulation owing to the high presence of healthcare and pharmaceutical industries. The APAC region has the largest population with a high prevalence of chronic diseases such as heart disease, cancer, diabetes, and others. For instance, according to Statista, there were over 4.5 million new cancer cases in China. The following figure shows the number of cancer patients with the type of cancer in China in the year 2020.

Due to this growing prevalence of such types of chronic diseases, market players and governments of various countries in the APAC region are more investing in the research and development of the new drug. For instance, in 2020 about around 722 clinical trials of the cancer drug were conducted in China. Thus, the growing R&D of the novel drug increases the demand for biosimulation technology that boosts the biosimulation market of the APAC region.

Europe is a rapidly growing region in the market of biosimulation due to growing research and development activities and high healthcare expenditure. In the Europe region growing prevalence of cancer thus the major players of this region are highly invested in the development of the drug. For instance, according to World Health Organization (WHO), there were a total of 2.7 million new cases of cancer excluding non-melanoma skin cancers and 1.3 million death occurs due to cancer. Thus, the government of Europe is more invested in the development of novel drugs. The pharmaceutical and biotechnological companies in this region increasing the launching of new drugs which rises the demand for biosimulation and also the growing adoption of the developed technology which supports the growth of the biosimulation market over the forecast period.

Top Key Players Covered In Biosimulation Market

• Certara(USA)
• Dassault Systemes (France)
• Advanced Chemistry Development (Canada)
• Simulation Plus (California)
• Schrodinger, Inc. (US)
• Chemical Computing Group ULC (Canada)
• Physiomics Plc (UK)
• Rosa & Co. LLC (US)
• BioSimulation Consulting Inc.
• Genedata AG (Switzerland)
• Instem Group of Companies (USA)
• PPD, Inc. (North Carolina)
• Yokogawa Insilico Biotechnology GmbH (Germany)
• Insilico Medicine (Hong Kong)
• Genedata (Switzerland)
• Physiomics Plc (UK)
• BioSimulation Consulting Inc. (US)
• Yokogawa Insilico Biotechnology GmbH (Germany)
• Immunetrics (US), and other major players.

Key Industry Development In The Biosimulation Market

• In June 2024, Simulations Plus, Inc a prominent provider of modeling and simulation software for pharmaceutical safety and efficacy, announced its acquisition of Pro-ficiency Holdings, Inc. and its subsidiaries. Pro-ficiency, a leader in simulation-enabled performance and intelligence solutions for clinical and commercial drug development, was acquired from QHP Capital, L.P. (the management company for NovaQuest Private Equity) and Pro-ficiency’s minority shareholders. The transaction, valued at approximately $100 million in cash, was completed to expand Simulations Plus's platform across the entire drug development continuum.
• In June 2024, Sun Pharmaceutical Industries Limited had agreed to acquire a 9.6% stake in Haystack Analytics Private Limited. HaystackAnalytics was involved in developing genomic analysis software that facilitated clinical decision-making. This software enabled comprehensive and rapid clinical genomics through culture-free methods, automating bioinformatic analysis to generate clear and clinically relevant reports. The genomic data and its analysis were utilized to create new healthcare products. The acquisition aimed to enhance Sun Pharma's capabilities in genomic analysis and contribute to advancements in healthcare products and decision-making processes.

Chapter 1: Introduction
 1.1 Research Objectives
 1.2 Research Methodology
 1.3 Research Process
 1.4 Scope and Coverage
  1.4.1 Market Definition
  1.4.2 Key Questions Answered
 1.5 Market Segmentation

Chapter 2:Executive Summary

Chapter 3:Growth Opportunities By Segment
 3.1 By Test Type
 3.2 By Application

Chapter 4: Market Landscape
 4.1 Porter's Five Forces Analysis
  4.1.1 Bargaining Power of Supplier
  4.1.2 Threat of New Entrants
  4.1.3 Threat of Substitutes
  4.1.4 Competitive Rivalry
  4.1.5 Bargaining Power Among Buyers
 4.2 Industry Value Chain Analysis
 4.3 Market Dynamics
  4.3.1 Drivers
  4.3.2 Restraints
  4.3.3 Opportunities
  4.5.4 Challenges
 4.4 Pestle Analysis
 4.5 Technological Roadmap
 4.6 Regulatory Landscape
 4.7 SWOT Analysis
 4.8 Price Trend Analysis
 4.9 Patent Analysis
 4.10 Analysis of the Impact of Covid-19
  4.10.1 Impact on the Overall Market
  4.10.2 Impact on the Supply Chain
  4.10.3 Impact on the Key Manufacturers
  4.10.4 Impact on the Pricing

Chapter 5: Biosimulation Market by Test Type
 5.1 Biosimulation Market Overview Snapshot and Growth Engine
 5.2 Biosimulation Market Overview
 5.3 ELISA
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size (2017-2032F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 ELISA: Geographic Segmentation
 5.4 Colorimetric
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size (2017-2032F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Colorimetric: Geographic Segmentation
 5.5 Spectrophotometric
  5.5.1 Introduction and Market Overview
  5.5.2 Historic and Forecasted Market Size (2017-2032F)
  5.5.3 Key Market Trends, Growth Factors and Opportunities
  5.5.4 Spectrophotometric: Geographic Segmentation

Chapter 6: Biosimulation Market by Application
 6.1 Biosimulation Market Overview Snapshot and Growth Engine
 6.2 Biosimulation Market Overview
 6.3 Hospital
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size (2017-2032F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Hospital: Geographic Segmentation
 6.4 Laboratory
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size (2017-2032F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Laboratory: Geographic Segmentation

Chapter 7: Company Profiles and Competitive Analysis
 7.1 Competitive Landscape
  7.1.1 Competitive Positioning
  7.1.2 Biosimulation Sales and Market Share By Players
  7.1.3 Industry BCG Matrix
  7.1.4 Heat Map Analysis
  7.1.5 Biosimulation Industry Concentration Ratio (CR5 and HHI)
  7.1.6 Top 5 Biosimulation Players Market Share
  7.1.7 Mergers and Acquisitions
  7.1.8 Business Strategies By Top Players
 7.2 CERTARA
  7.2.1 Company Overview
  7.2.2 Key Executives
  7.2.3 Company Snapshot
  7.2.4 Operating Business Segments
  7.2.5 Product Portfolio
  7.2.6 Business Performance
  7.2.7 Key Strategic Moves and Recent Developments
  7.2.8 SWOT Analysis
 7.3 DASSAULT SYSTEMES
 7.4 ADVANCED CHEMISTRY DEVELOPMENT
 7.5 SIMULATION PLUS
 7.6 SCHRODINGER
 7.7 INC.
 7.8 CHEMICAL COMPUTING GROUP ULC
 7.9 PHYSIOMICS PLC
 7.10 ROSA & CO. LLC
 7.11 BIOSIMULATION CONSULTING INC.
 7.12 GENEDATA AG
 7.13 INSTEM GROUP OF COMPANIES
 7.14 PPD INC.
 7.15 YOKOGAWA INSILICO BIOTECHNOLOGY GMBH
 7.16 IMMUNETRICS
 7.17 OTHER MAJOR PLAYERS

Chapter 8: Global Biosimulation Market Analysis, Insights and Forecast, 2017-2032
 8.1 Market Overview
 8.2 Historic and Forecasted Market Size By Test Type
  8.2.1 ELISA
  8.2.2 Colorimetric
  8.2.3 Spectrophotometric
 8.3 Historic and Forecasted Market Size By Application
  8.3.1 Hospital
  8.3.2 Laboratory

Chapter 9: North America Biosimulation Market Analysis, Insights and Forecast, 2017-2032
 9.1 Key Market Trends, Growth Factors and Opportunities
 9.2 Impact of Covid-19
 9.3 Key Players
 9.4 Key Market Trends, Growth Factors and Opportunities
 9.4 Historic and Forecasted Market Size By Test Type
  9.4.1 ELISA
  9.4.2 Colorimetric
  9.4.3 Spectrophotometric
 9.5 Historic and Forecasted Market Size By Application
  9.5.1 Hospital
  9.5.2 Laboratory
 9.6 Historic and Forecast Market Size by Country
  9.6.1 U.S.
  9.6.2 Canada
  9.6.3 Mexico

Chapter 10: Europe Biosimulation Market Analysis, Insights and Forecast, 2017-2032
 10.1 Key Market Trends, Growth Factors and Opportunities
 10.2 Impact of Covid-19
 10.3 Key Players
 10.4 Key Market Trends, Growth Factors and Opportunities
 10.4 Historic and Forecasted Market Size By Test Type
  10.4.1 ELISA
  10.4.2 Colorimetric
  10.4.3 Spectrophotometric
 10.5 Historic and Forecasted Market Size By Application
  10.5.1 Hospital
  10.5.2 Laboratory
 10.6 Historic and Forecast Market Size by Country
  10.6.1 Germany
  10.6.2 U.K.
  10.6.3 France
  10.6.4 Italy
  10.6.5 Russia
  10.6.6 Spain
  10.6.7 Rest of Europe

Chapter 11: Asia-Pacific Biosimulation Market Analysis, Insights and Forecast, 2017-2032
 11.1 Key Market Trends, Growth Factors and Opportunities
 11.2 Impact of Covid-19
 11.3 Key Players
 11.4 Key Market Trends, Growth Factors and Opportunities
 11.4 Historic and Forecasted Market Size By Test Type
  11.4.1 ELISA
  11.4.2 Colorimetric
  11.4.3 Spectrophotometric
 11.5 Historic and Forecasted Market Size By Application
  11.5.1 Hospital
  11.5.2 Laboratory
 11.6 Historic and Forecast Market Size by Country
  11.6.1 China
  11.6.2 India
  11.6.3 Japan
  11.6.4 Singapore
  11.6.5 Australia
  11.6.6 New Zealand
  11.6.7 Rest of APAC

Chapter 12: Middle East & Africa Biosimulation Market Analysis, Insights and Forecast, 2017-2032
 12.1 Key Market Trends, Growth Factors and Opportunities
 12.2 Impact of Covid-19
 12.3 Key Players
 12.4 Key Market Trends, Growth Factors and Opportunities
 12.4 Historic and Forecasted Market Size By Test Type
  12.4.1 ELISA
  12.4.2 Colorimetric
  12.4.3 Spectrophotometric
 12.5 Historic and Forecasted Market Size By Application
  12.5.1 Hospital
  12.5.2 Laboratory
 12.6 Historic and Forecast Market Size by Country
  12.6.1 Turkey
  12.6.2 Saudi Arabia
  12.6.3 Iran
  12.6.4 UAE
  12.6.5 Africa
  12.6.6 Rest of MEA

Chapter 13: South America Biosimulation Market Analysis, Insights and Forecast, 2017-2032
 13.1 Key Market Trends, Growth Factors and Opportunities
 13.2 Impact of Covid-19
 13.3 Key Players
 13.4 Key Market Trends, Growth Factors and Opportunities
 13.4 Historic and Forecasted Market Size By Test Type
  13.4.1 ELISA
  13.4.2 Colorimetric
  13.4.3 Spectrophotometric
 13.5 Historic and Forecasted Market Size By Application
  13.5.1 Hospital
  13.5.2 Laboratory
 13.6 Historic and Forecast Market Size by Country
  13.6.1 Brazil
  13.6.2 Argentina
  13.6.3 Rest of SA

Chapter 14 Investment Analysis

Chapter 15 Analyst Viewpoint and Conclusion

LIST OF TABLES

TABLE 001. EXECUTIVE SUMMARY
TABLE 002. BIOSIMULATION MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. BIOSIMULATION MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. BIOSIMULATION MARKET COMPETITIVE RIVALRY
TABLE 005. BIOSIMULATION MARKET THREAT OF NEW ENTRANTS
TABLE 006. BIOSIMULATION MARKET THREAT OF SUBSTITUTES
TABLE 007. BIOSIMULATION MARKET BY TEST TYPE
TABLE 008. ELISA MARKET OVERVIEW (2016-2028)
TABLE 009. COLORIMETRIC MARKET OVERVIEW (2016-2028)
TABLE 010. SPECTROPHOTOMETRIC MARKET OVERVIEW (2016-2028)
TABLE 011. BIOSIMULATION MARKET BY APPLICATION
TABLE 012. HOSPITAL MARKET OVERVIEW (2016-2028)
TABLE 013. LABORATORY MARKET OVERVIEW (2016-2028)
TABLE 014. NORTH AMERICA BIOSIMULATION MARKET, BY TEST TYPE (2016-2028)
TABLE 015. NORTH AMERICA BIOSIMULATION MARKET, BY APPLICATION (2016-2028)
TABLE 016. N BIOSIMULATION MARKET, BY COUNTRY (2016-2028)
TABLE 017. EUROPE BIOSIMULATION MARKET, BY TEST TYPE (2016-2028)
TABLE 018. EUROPE BIOSIMULATION MARKET, BY APPLICATION (2016-2028)
TABLE 019. BIOSIMULATION MARKET, BY COUNTRY (2016-2028)
TABLE 020. ASIA PACIFIC BIOSIMULATION MARKET, BY TEST TYPE (2016-2028)
TABLE 021. ASIA PACIFIC BIOSIMULATION MARKET, BY APPLICATION (2016-2028)
TABLE 022. BIOSIMULATION MARKET, BY COUNTRY (2016-2028)
TABLE 023. MIDDLE EAST & AFRICA BIOSIMULATION MARKET, BY TEST TYPE (2016-2028)
TABLE 024. MIDDLE EAST & AFRICA BIOSIMULATION MARKET, BY APPLICATION (2016-2028)
TABLE 025. BIOSIMULATION MARKET, BY COUNTRY (2016-2028)
TABLE 026. SOUTH AMERICA BIOSIMULATION MARKET, BY TEST TYPE (2016-2028)
TABLE 027. SOUTH AMERICA BIOSIMULATION MARKET, BY APPLICATION (2016-2028)
TABLE 028. BIOSIMULATION MARKET, BY COUNTRY (2016-2028)
TABLE 029. CERTARA: SNAPSHOT
TABLE 030. CERTARA: BUSINESS PERFORMANCE
TABLE 031. CERTARA: PRODUCT PORTFOLIO
TABLE 032. CERTARA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 032. DASSAULT SYSTEMES: SNAPSHOT
TABLE 033. DASSAULT SYSTEMES: BUSINESS PERFORMANCE
TABLE 034. DASSAULT SYSTEMES: PRODUCT PORTFOLIO
TABLE 035. DASSAULT SYSTEMES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 035. ADVANCED CHEMISTRY DEVELOPMENT: SNAPSHOT
TABLE 036. ADVANCED CHEMISTRY DEVELOPMENT: BUSINESS PERFORMANCE
TABLE 037. ADVANCED CHEMISTRY DEVELOPMENT: PRODUCT PORTFOLIO
TABLE 038. ADVANCED CHEMISTRY DEVELOPMENT: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 038. SIMULATION PLUS: SNAPSHOT
TABLE 039. SIMULATION PLUS: BUSINESS PERFORMANCE
TABLE 040. SIMULATION PLUS: PRODUCT PORTFOLIO
TABLE 041. SIMULATION PLUS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 041. SCHRODINGER: SNAPSHOT
TABLE 042. SCHRODINGER: BUSINESS PERFORMANCE
TABLE 043. SCHRODINGER: PRODUCT PORTFOLIO
TABLE 044. SCHRODINGER: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 044. INC.: SNAPSHOT
TABLE 045. INC.: BUSINESS PERFORMANCE
TABLE 046. INC.: PRODUCT PORTFOLIO
TABLE 047. INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 047. CHEMICAL COMPUTING GROUP ULC: SNAPSHOT
TABLE 048. CHEMICAL COMPUTING GROUP ULC: BUSINESS PERFORMANCE
TABLE 049. CHEMICAL COMPUTING GROUP ULC: PRODUCT PORTFOLIO
TABLE 050. CHEMICAL COMPUTING GROUP ULC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 050. PHYSIOMICS PLC: SNAPSHOT
TABLE 051. PHYSIOMICS PLC: BUSINESS PERFORMANCE
TABLE 052. PHYSIOMICS PLC: PRODUCT PORTFOLIO
TABLE 053. PHYSIOMICS PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 053. ROSA & CO. LLC: SNAPSHOT
TABLE 054. ROSA & CO. LLC: BUSINESS PERFORMANCE
TABLE 055. ROSA & CO. LLC: PRODUCT PORTFOLIO
TABLE 056. ROSA & CO. LLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 056. BIOSIMULATION CONSULTING INC.: SNAPSHOT
TABLE 057. BIOSIMULATION CONSULTING INC.: BUSINESS PERFORMANCE
TABLE 058. BIOSIMULATION CONSULTING INC.: PRODUCT PORTFOLIO
TABLE 059. BIOSIMULATION CONSULTING INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 059. GENEDATA AG: SNAPSHOT
TABLE 060. GENEDATA AG: BUSINESS PERFORMANCE
TABLE 061. GENEDATA AG: PRODUCT PORTFOLIO
TABLE 062. GENEDATA AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 062. INSTEM GROUP OF COMPANIES: SNAPSHOT
TABLE 063. INSTEM GROUP OF COMPANIES: BUSINESS PERFORMANCE
TABLE 064. INSTEM GROUP OF COMPANIES: PRODUCT PORTFOLIO
TABLE 065. INSTEM GROUP OF COMPANIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 065. PPD INC.: SNAPSHOT
TABLE 066. PPD INC.: BUSINESS PERFORMANCE
TABLE 067. PPD INC.: PRODUCT PORTFOLIO
TABLE 068. PPD INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 068. YOKOGAWA INSILICO BIOTECHNOLOGY GMBH: SNAPSHOT
TABLE 069. YOKOGAWA INSILICO BIOTECHNOLOGY GMBH: BUSINESS PERFORMANCE
TABLE 070. YOKOGAWA INSILICO BIOTECHNOLOGY GMBH: PRODUCT PORTFOLIO
TABLE 071. YOKOGAWA INSILICO BIOTECHNOLOGY GMBH: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 071. IMMUNETRICS: SNAPSHOT
TABLE 072. IMMUNETRICS: BUSINESS PERFORMANCE
TABLE 073. IMMUNETRICS: PRODUCT PORTFOLIO
TABLE 074. IMMUNETRICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 074. OTHER MAJOR PLAYERS: SNAPSHOT
TABLE 075. OTHER MAJOR PLAYERS: BUSINESS PERFORMANCE
TABLE 076. OTHER MAJOR PLAYERS: PRODUCT PORTFOLIO
TABLE 077. OTHER MAJOR PLAYERS: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. BIOSIMULATION MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. BIOSIMULATION MARKET OVERVIEW BY TEST TYPE
FIGURE 012. ELISA MARKET OVERVIEW (2016-2028)
FIGURE 013. COLORIMETRIC MARKET OVERVIEW (2016-2028)
FIGURE 014. SPECTROPHOTOMETRIC MARKET OVERVIEW (2016-2028)
FIGURE 015. BIOSIMULATION MARKET OVERVIEW BY APPLICATION
FIGURE 016. HOSPITAL MARKET OVERVIEW (2016-2028)
FIGURE 017. LABORATORY MARKET OVERVIEW (2016-2028)
FIGURE 018. NORTH AMERICA BIOSIMULATION MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 019. EUROPE BIOSIMULATION MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 020. ASIA PACIFIC BIOSIMULATION MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 021. MIDDLE EAST & AFRICA BIOSIMULATION MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 022. SOUTH AMERICA BIOSIMULATION MARKET OVERVIEW BY COUNTRY (2016-2028)